Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Profile of Depressive Symptoms in Parkinsons Disease

Completed

Conditions: Depression
Parkinson Disease

First Posted Date: 2006-07-06

Last Posted Date: 2023-12-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1018

Registration Number: NCT00349310

Locations: 🇫🇷
Hopital Purpan, Toulouse cedex, France
🇬🇧
Boehringer Ingelheim Investigational Site, Newark, United Kingdom
🇩🇪
Parkinson Klinik Wolfach, Wolfach, Germany

and more 15 locations

Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.

Phase 3

Completed

Conditions: Sleep Initiation and Maintenance Disorders

First Posted Date: 2006-07-04

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 253

Registration Number: NCT00347295

Locations: 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Shanghai Mental Health Center, Shanghai, China

and more 5 locations

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Phase 2

Completed

Conditions: Bladder, Neurogenic

Interventions: Drug: tamsulosin hydrochloride

First Posted Date: 2006-06-21

Last Posted Date: 2016-02-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 143

Registration Number: NCT00340704

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: BIRT 2584 XX
Drug: Placebo

First Posted Date: 2006-06-05

Last Posted Date: 2014-06-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 360

Registration Number: NCT00333411

Locations: 🇫🇷
Hôpital Dupuytren, Limoges cedex 1, France
🇩🇪
Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
🇩🇪
Johannes Gutenberg-Universität Mainz, Mainz, Germany

and more 36 locations

Secondary Prevention of Venous Thrombo Embolism (VTE).

Phase 3

Completed

Conditions: Thromboembolism

Interventions: Drug: Dabigatran
Drug: Warfarin

First Posted Date: 2006-05-24

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2867

Registration Number: NCT00329238

Locations: 🇺🇸
1160.47.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States
🇨🇦
1160.47.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇲🇽
1160.47.52030 Boehringer Ingelheim Investigational Site, Guadalajara, Jal., Mexico

and more 272 locations

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: BI 1356 dose 1 once daily
Drug: BI 1356 dose 2 once daily
Drug: BI 1356 dose 3 once daily
Drug: Metformin

First Posted Date: 2006-05-19

Last Posted Date: 2014-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 302

Registration Number: NCT00328172

Locations: 🇺🇸
1218.5.10026 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇨🇦
1218.5.11002 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇺🇸
1218.5.10016 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States

and more 68 locations

Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-05-17

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 184

Registration Number: NCT00326768

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: pramipexole

First Posted Date: 2006-05-04

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 535

Registration Number: NCT00321854

Locations: 🇺🇸
248.595.0102 Boehringer Ingelheim Investigational Site, Traverse City, Michigan, United States
🇺🇸
248.595.0103 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇮🇹
248.595.39012 Azienda Ospedaliera Pisana- Università degli Studi di Pisa, Pisa, Italy

and more 96 locations

General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-04-27

Last Posted Date: 2023-12-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8000

Registration Number: NCT00319813

Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia

Phase 3

Completed

Conditions: Hypertension
Dyslipidemias

First Posted Date: 2006-04-20

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1695

Registration Number: NCT00316095

Locations: 🇫🇷
ALTI, Angers, France
🇰🇷
Hallym University Sacred Heart Hospital, Kyunggi-do, Korea, Republic of
🇳🇱
Andromed Eindhoven, Eindhoven, Netherlands

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy